Data from Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Year: 2023
Type: other
Abstract: PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. We performed comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti–PD-L1 therapy. We discovered activating somatic and germline amino acid variants in JAK3 that promoted PD-L1 induction in lung cancer cells and in the tumor immune microenvironment. These findings suggest that genomic alterations that deregulate cytokine receptor signal transduction could contribute to PD-L1 activation and engagement of the PD-1 immune checkpoint in lung cancer. Cancer Immunol Res; 3(8); 855–63. ©2015 AACR.
Authors: Eliezer M. Van Allen, Hadrien G. Golay, Yan Liu, Shohei Koyama, Karrie Wong, Amaro Taylor-Weiner, Marios Giannakis, Maegan Harden, Vanesa Rojas-Rudilla, Aaron Chevalier, Tran Thai, Christine Lydon, Stacy Mach, Ada G. Avila, Joshua A. Wong, Alexandra R. Rabin, Joshua Helmkamp, Lynette Sholl, Scott L. Carter, Geoffrey Oxnard, Pasi Janne, Gad Getz, Neal Lindeman, Peter S. Hammerman, Levi A. Garraway, F. Stephen Hodi, Scott J. Rodig, Glenn Dranoff, Kwok-Kin Wong, David A. Barbie
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362545926